Pharmaceutical company GlaxoSmithKline Plc (GSK) said on Tuesday its Covid-19 antibody treatment is effective against the full combination of mutations in the new Omicron variant, citing new data from early-stage research. The London-based drug maker declared in a statement that the tests done in-vitro against a pseudo-virus that recreates a synthesized version of Omicron showed that Sotrovimab, Glaxo’s antibody treatment, stands up to all mutations in the spike protein of ...